替罗非班联合不同剂量瑞舒伐他汀治疗急性心肌梗死的可行性对比

Feasibility Comparison of Tirofiban Combined with Different doses of Rosuvastatin in the Treatment of Acute Myocardial Infarction

目的对替罗非班联合不同剂量瑞舒伐他汀治疗急性心肌梗死的可行性进行探讨,评价其临床治疗效果与安全性。方法在我院2014年~2015年收治的127例急性心肌梗死患者中抽取78例符合本次研究条件的患者作为本次研究对象,按照随机分组的方法将本次所纳入的病例随机分为观察组与对照组,观察组泵入替罗非班+20 mg瑞士伐他汀治疗;对照组泵入替罗非班+10 mg瑞舒伐他汀,两组患者均连续接受为期12个月的治疗,将两组患者治疗后TG、TC、LDC等指标水平作以比较,观察随访14个月后患者再发心血管事件发生率。结果治疗后两组患者血清中TG、TC、LDC含量均有所降低,观察组降低幅度明显优于对照组,组间差异具备统计学意义(P<0.05);观察组心血管事件再发发生率为15.4%明显低于对照组30.8%,两组差异有统计学意义(P<0.05)。结论替罗非班联合大剂量剂量瑞舒伐他汀治疗急性心肌梗死临床疗效确切,显著降低患者血清中G、TC、LDC含量,患者再发心血管事件发生率明显下降,临床应用安全可靠,效果肯定,可以作为治疗急性心肌梗死的常规疗法。

Objective To evaluate the feasibility of tirofiban combined with different doses of rosuvastatin in the treatment of acute myocardial infarction, and to evaluate its clinical efficacy and safety. Methods A total of 78 patients with acute myocardial infarction admitted to our hospital from 2014 to 2015 were selected as the subjects of this study. According to the method of randomization, the cases included in this study were randomly divided into observation. The control group was treated with tirofiban ＋ 10 mg rosuvastatin and the control group was treated with tirofiban ＋ 10 mg rosuvastatin. The patients in the two groups received continuous treatment for 12 months. After treatment, the two groups were treated TG, TC, LDC and other indicators of the level of comparison to observe the follow-up 14 months after the recurrence of cardiovascular events in patients with the incidence. Results The levels of TG, TC and LDC in the serum of the two groups were significantly lower than those in the control group （P〈0.05）. The cardiovascular events were observed in the observation group The incidence was 15.4% was significantly lower than the control group 30.8%, the difference between the two groups was statistically significant （P〈0.05）. Conclusion The clinical efficacy of tirofiban combined with high dose dose of rosuvastatin in the treatment of acute myocardial infarction is significantly reduced, the content of G, TC and LDC in patients＇ serum is significantly reduced, the incidence of recurrent cardiovascular events is significantly decreased, the clinical application is safe and reliable, Surely, can be used as a routine therapy for the treatment of acute myocardial infarction.